1036 related articles for article (PubMed ID: 26972336)
21. Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
Mills AM; Peres LC; Meiss A; Ring KL; Modesitt SC; Abbott SE; Alberg AJ; Bandera EV; Barnholtz-Sloan J; Bondy ML; Cote ML; Funkhouser E; Moorman PG; Peters ES; Schwartz AG; Terry PD; Wallace K; Schildkraut JM
Int J Gynecol Pathol; 2019 Mar; 38(2):157-170. PubMed ID: 29485423
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
23. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
24. Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors.
Gottlieb CE; Mills AM; Cross JV; Ring KL
Gynecol Oncol; 2017 Mar; 144(3):607-612. PubMed ID: 28065619
[TBL] [Abstract][Full Text] [Related]
25. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
26. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
[TBL] [Abstract][Full Text] [Related]
27. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
[TBL] [Abstract][Full Text] [Related]
28. Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer.
Kroeger DR; Milne K; Nelson BH
Clin Cancer Res; 2016 Jun; 22(12):3005-15. PubMed ID: 26763251
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
Duraiswamy J; Freeman GJ; Coukos G
Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
[TBL] [Abstract][Full Text] [Related]
30. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
Wan C; Keany MP; Dong H; Al-Alem LF; Pandya UM; Lazo S; Boehnke K; Lynch KN; Xu R; Zarrella DT; Gu S; Cejas P; Lim K; Long HW; Elias KM; Horowitz NS; Feltmate CM; Muto MG; Worley MJ; Berkowitz RS; Matulonis UA; Nucci MR; Crum CP; Rueda BR; Brown M; Liu XS; Hill SJ
Cancer Res; 2021 Jan; 81(1):158-173. PubMed ID: 33158814
[TBL] [Abstract][Full Text] [Related]
31. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
[TBL] [Abstract][Full Text] [Related]
32. Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status.
Whitehair R; Peres LC; Mills AM
Int J Gynecol Pathol; 2020 Nov; 39(6):558-566. PubMed ID: 31851060
[TBL] [Abstract][Full Text] [Related]
33. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4
Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI
Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422
[TBL] [Abstract][Full Text] [Related]
34. Discordance of PD-L1 expression in primary and metastatic ovarian high-grade serous carcinoma and its correlation with CD8 + tumor-infiltrating lymphocytes and patient prognosis.
Zhang T; Zhou X; Zhang X; Niu S; Chen H; Zhou F
Virchows Arch; 2023 Apr; 482(4):755-766. PubMed ID: 36806916
[TBL] [Abstract][Full Text] [Related]
35. CD25 identifies a subset of CD4⁺FoxP3⁻ TIL that are exhausted yet prognostically favorable in human ovarian cancer.
deLeeuw RJ; Kroeger DR; Kost SE; Chang PP; Webb JR; Nelson BH
Cancer Immunol Res; 2015 Mar; 3(3):245-53. PubMed ID: 25480168
[TBL] [Abstract][Full Text] [Related]
36. Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma.
Nam SJ; Kim YH; Park JE; Ra YS; Khang SK; Cho YH; Kim JH; Sung CO
Cancer Immunol Immunother; 2019 Feb; 68(2):305-318. PubMed ID: 30483834
[TBL] [Abstract][Full Text] [Related]
37. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
[TBL] [Abstract][Full Text] [Related]
38. Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer.
De La Motte Rouge T; Corné J; Cauchois A; Le Boulch M; Poupon C; Henno S; Rioux-Leclercq N; Le Pabic E; Laviolle B; Catros V; Levêque J; Fautrel A; Le Gallo M; Legembre P; Lavoué V
Mol Cancer Res; 2019 Dec; 17(12):2537-2548. PubMed ID: 31537619
[TBL] [Abstract][Full Text] [Related]
39. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
40. Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma.
Henriksen JR; Donskov F; Waldstrøm M; Jakobsen A; Hjortkjaer M; Petersen CB; Dahl Steffensen K
Acta Oncol; 2020 Jun; 59(6):652-659. PubMed ID: 31931651
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
